Raza Ur Rahman
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Raza Ur Rahman has a total of 80 co-authors. Here are the top co-authors by number of shared publications:
- Nusrat Husain
The University of Manchester, UK
7 shared publications - Imran Bashir Chaudhry
Faculty of Medicine, Biology and Health, University of Manchester, Manchester, UK
4 shared publications - Mohammad M Hamirani
Department of Psychiatry, Abbasi Shaheed Hospital, Karachi, Pakistan
3 shared publications - Nasir Mehmood
Karwan e Hayat Institute for mental health care
3 shared publications - Peter Michael Haddad
University of Manchester
3 shared publications - Tayyeba Kiran
Division of Mood Disorder, Pakistan Institute of Living and Learning, Karachi, Pakistan
3 shared publications
Latest Publications
- Open Access
- 1 July 2026
- Published by BMJ in BMJ Public Health
- Vol. 4 (3) , e005182
Prevalence and sociodemographic correlates of mental and behavioural disorders in Pakistan: findings from the first nationally representative cross-sectional survey
Introduction: Comprehensive population-based nationally representative data on the prevalence of mental and behavioural disorders in Pakistan (population 247 million) have been lacking—hindering the development of prevention policies and responsive mental health services. We conducted the National Psychiatric Morbidity Survey to ascertain the prevalence and sociodemographic correlates of these disorders to inform the development of mental healthcare policies to reduce stigma, disability and morbidity associated with these disorders. Methods: We conducted a cross-sectional household survey using a stratified multistage cluster sampling design across the four provinces of Pakistan between 2019 and 2022. A total of 17 773 adults aged ≥18 years were interviewed in-person by trained researchers using the Mini International Neuropsychiatric Interview (V.7.0.2). Current (point) and lifetime precise and weighted prevalence was determined according to the International Classification of Diseases ICD-10 classification of mental and behavioural disorders. Functional impairment was measured using the Sheehan Disability Scale. Weighted prevalence estimates and multivariable logistic regression were used to assess associations with sociodemographic variables. National Bioethics Committee of Pakistan granted ethical approval for the survey. Results: The overall current and lifetime weighted prevalence of all mental and behavioural disorders (ICD-10 codes, F10–F60) was 32.3% (95% CI 31.6 to 32.9) and 37.9% (95% CI 37.2 to 38.6), respectively. The highest current prevalence (24.5%) was observed for neurotic/stress-related disorders (F40–F48), followed by post-traumatic stress disorder (PTSD) (F43.1, 19.9%) and mood disorders (F30–F39, 11.6%)—which was essentially due to the high prevalence of episodic/recurrent depressive disorders (F32–F33, 10.6%). About 6% of the participants reported suicidality in the past month and 1% had made a lifetime suicide attempt. The highest prevalence was observed in people who were aged 40+ years, females, lived in urban areas, separated, divorced or widowed, had no formal education and were retired or categorised as homemakers. In the multivariable logistic regression analyses, the likelihood of psychiatric morbidity significantly increased with increasing age (p value for trend <0.001), being separated, divorced or widowed (p value for trend <0.01) and being unemployed, homemaker, student or retired (p value for trend <0.01) and decreased with increasing level of education and income (p value for trend <0.01) and residence in rural area. Conclusion: This first nationally representative survey of psychiatric morbidity in Pakistan showed that one in three adults in the country is living with a diagnosable mental and behavioural disorder. The relatively high prevalence of PTSD (1 in 5) may be associated with broader contextual factors, although the cross-sectional design does not permit attribution to specific events or exposures. These findings inform the development of national mental health prevention strategy, healthcare services and community support programmes to reduce the burden of psychiatric morbidity in Pakistan.
- 1 July 2026
- Published by BMJ in BMJ Public Health
- Vol. 4 (3) , e005182
Open AccessPrevalence and sociodemographic correlates of mental and behavioural disorders in Pakistan: findings from the first nationally representative cross-sectional survey
Introduction: Comprehensive population-based nationally representative data on the prevalence of mental and behavioural disorders in Pakistan (population 247 million) have been lacking—hindering the development of prevention policies and responsive mental health services. We conducted the National Psychiatric Morbidity Survey to ascertain the prevalence and sociodemographic correlates of these disorders to inform the development of mental healthcare policies to reduce stigma, disability and morbidity associated with these disorders. Methods: We conducted a cross-sectional household survey using a stratified multistage cluster sampling design across the four provinces of Pakistan between 2019 and 2022. A total of 17 773 adults aged ≥18 years were interviewed in-person by trained researchers using the Mini International Neuropsychiatric Interview (V.7.0.2). Current (point) and lifetime precise and weighted prevalence was determined according to the International Classification of Diseases ICD-10 classification of mental and behavioural disorders. Functional impairment was measured using the Sheehan Disability Scale. Weighted prevalence estimates and multivariable logistic regression were used to assess associations with sociodemographic variables. National Bioethics Committee of Pakistan granted ethical approval for the survey. Results: The overall current and lifetime weighted prevalence of all mental and behavioural disorders (ICD-10 codes, F10–F60) was 32.3% (95% CI 31.6 to 32.9) and 37.9% (95% CI 37.2 to 38.6), respectively. The highest current prevalence (24.5%) was observed for neurotic/stress-related disorders (F40–F48), followed by post-traumatic stress disorder (PTSD) (F43.1, 19.9%) and mood disorders (F30–F39, 11.6%)—which was essentially due to the high prevalence of episodic/recurrent depressive disorders (F32–F33, 10.6%). About 6% of the participants reported suicidality in the past month and 1% had made a lifetime suicide attempt. The highest prevalence was observed in people who were aged 40+ years, females, lived in urban areas, separated, divorced or widowed, had no formal education and were retired or categorised as homemakers. In the multivariable logistic regression analyses, the likelihood of psychiatric morbidity significantly increased with increasing age (p value for trend <0.001), being separated, divorced or widowed (p value for trend <0.01) and being unemployed, homemaker, student or retired (p value for trend <0.01) and decreased with increasing level of education and income (p value for trend <0.01) and residence in rural area. Conclusion: This first nationally representative survey of psychiatric morbidity in Pakistan showed that one in three adults in the country is living with a diagnosable mental and behavioural disorder. The relatively high prevalence of PTSD (1 in 5) may be associated with broader contextual factors, although the cross-sectional design does not permit attribution to specific events or exposures. These findings inform the development of national mental health prevention strategy, healthcare services and community support programmes to reduce the burden of psychiatric morbidity in Pakistan.
- Open Access
- 1 September 2021
- Published by Springer Nature in Translational Psychiatry
- Vol. 11 (1) , 1
Correction: A randomised clinical trial of methotrexate points to possible efficacy and adaptive immune dysfunction in psychosis
- 1 September 2021
- Published by Springer Nature in Translational Psychiatry
- Vol. 11 (1) , 1
Open AccessCorrection: A randomised clinical trial of methotrexate points to possible efficacy and adaptive immune dysfunction in psychosis
- Open Access
Oasis2.0: improved online analysis of small RNA-seq data
Oasis 2 is a new main release of the Oasis web application for the detection, differential expression, and classification of small RNAs in deep sequencing data. Compared to its predecessor Oasis, Oasis 2 features a novel and speed-optimized sRNA detection module that supports the identification of small RNAs in any organism with higher accuracy. Next to the improved detection of small RNAs in a target organism, the software now also recognizes potential cross-species miRNAs and viral and bacterial sRNAs in infected samples. In addition, novel miRNAs can now be queried and visualized interactively, providing essential information for over 700 high-quality miRNA predictions across 14 organisms. Robust biomarker signatures can now be obtained using the novel enhanced classification module. Oasis 2 enables biologists and medical researchers to rapidly analyze and query small RNA deep sequencing data with improved precision, recall, and speed, in an interactive and user-friendly environment. Availability and Implementation: Oasis 2 is implemented in Java, J2EE, mysql, Python, R, PHP and JavaScript. It is freely available at http://oasis.dzne.de
Open AccessOasis2.0: improved online analysis of small RNA-seq data
Oasis 2 is a new main release of the Oasis web application for the detection, differential expression, and classification of small RNAs in deep sequencing data. Compared to its predecessor Oasis, Oasis 2 features a novel and speed-optimized sRNA detection module that supports the identification of small RNAs in any organism with higher accuracy. Next to the improved detection of small RNAs in a target organism, the software now also recognizes potential cross-species miRNAs and viral and bacterial sRNAs in infected samples. In addition, novel miRNAs can now be queried and visualized interactively, providing essential information for over 700 high-quality miRNA predictions across 14 organisms. Robust biomarker signatures can now be obtained using the novel enhanced classification module. Oasis 2 enables biologists and medical researchers to rapidly analyze and query small RNA deep sequencing data with improved precision, recall, and speed, in an interactive and user-friendly environment. Availability and Implementation: Oasis 2 is implemented in Java, J2EE, mysql, Python, R, PHP and JavaScript. It is freely available at http://oasis.dzne.de
- Open Access
The landscape of human mutually exclusive splicing
Mutually exclusive splicing of exons is a mechanism of functional gene and protein diversification with pivotal roles in organismal development and diseases such as Timothy syndrome, cardiomyopathy and cancer in humans. In order to obtain a first genome-wide estimate of the extent and biological role of mutually exclusive splicing in humans we predicted and subsequently validated mutually exclusive exons (MXEs) using 515 publically available RNA-seq datasets. Here, we provide evidence for the expression of over 855 MXEs, 42% of which represent novel exons, increasing the annotated human mutually exclusive exome more than five-fold. The data provides strong evidence for the existence of large and multi-cluster MXEs in higher vertebrates and offers new insights into MXE splicing mechanics and evolution. Finally, MXEs are significantly enriched in pathogenic mutations and their spatio-temporal expression predicts human disease pathology.
Open AccessThe landscape of human mutually exclusive splicing
Mutually exclusive splicing of exons is a mechanism of functional gene and protein diversification with pivotal roles in organismal development and diseases such as Timothy syndrome, cardiomyopathy and cancer in humans. In order to obtain a first genome-wide estimate of the extent and biological role of mutually exclusive splicing in humans we predicted and subsequently validated mutually exclusive exons (MXEs) using 515 publically available RNA-seq datasets. Here, we provide evidence for the expression of over 855 MXEs, 42% of which represent novel exons, increasing the annotated human mutually exclusive exome more than five-fold. The data provides strong evidence for the existence of large and multi-cluster MXEs in higher vertebrates and offers new insights into MXE splicing mechanics and evolution. Finally, MXEs are significantly enriched in pathogenic mutations and their spatio-temporal expression predicts human disease pathology.
- Open Access
- 11 February 2017
- Published by Springer Nature in International Journal of Bipolar Disorders
- Vol. 5 (1) , 1-9
Pilot study of a culturally adapted psychoeducation (CaPE) intervention for bipolar disorder in Pakistan
Background: Despite the use of maintenance medication, recurrence rates in bipolar affective disorder (BPAD) are high. To date, there are no clinical trials that have investigated the use of psychological interventions in bipolar disorder in Pakistan. Aim: The purpose of the study was to assess the feasibility and acceptability of a culturally adapted bipolar psychoeducation programme (CaPE) in Pakistan. Methods: Thirty-four euthymic bipolar I and II outpatients were randomized to either 12 weekly sessions of individual psychoeducation plus Treatment As Usual (Intervention) or Treatment As Usual (TAU) (Control). Outcomes were assessed using the Young Mania Rating Scale (YMRS), Beck Depression Inventory (BDI), EuroQoL (EQ-5D), Bipolar Knowledge and Attitudes and Questionnaire (BKAQ), and a self-reported measure of medication adherence (Morisky Medication Adherence Scale-4 items, MMAS-4). Effect sizes were derived from baseline adjusted standardized regression coefficients. Results: Retention in the study was good, 80% of patients in the TAU follow-up assessment and 100% of patients in the CaPE group attended all 12 sessions. Patient satisfaction was higher in the CaPE group relative to control (ES = 1.41). Further, there were large effect sizes shown for CaPE versus TAU for medication adherence (MMAS-4: ES = 0.81), knowledge and attitudes towards bipolar (BKAQ: ES = 0.68), mania (YMRS: ES = 1.18), depression (BDI: ES = 1.17) and quality of life measures (EQ-5D: ES ⇒ 0.88). Conclusions: Culturally adapted psychoeducation intervention is acceptable and feasible, and can be effective in improving mood symptoms and knowledge and attitudes to BPAD when compared with TAU. Larger scale studies are needed to confirm our findings. Trial registration. Clinicaltrials.gov identifier NCT02210390
- 11 February 2017
- Published by Springer Nature in International Journal of Bipolar Disorders
- Vol. 5 (1) , 1-9
Open AccessPilot study of a culturally adapted psychoeducation (CaPE) intervention for bipolar disorder in Pakistan
Background: Despite the use of maintenance medication, recurrence rates in bipolar affective disorder (BPAD) are high. To date, there are no clinical trials that have investigated the use of psychological interventions in bipolar disorder in Pakistan. Aim: The purpose of the study was to assess the feasibility and acceptability of a culturally adapted bipolar psychoeducation programme (CaPE) in Pakistan. Methods: Thirty-four euthymic bipolar I and II outpatients were randomized to either 12 weekly sessions of individual psychoeducation plus Treatment As Usual (Intervention) or Treatment As Usual (TAU) (Control). Outcomes were assessed using the Young Mania Rating Scale (YMRS), Beck Depression Inventory (BDI), EuroQoL (EQ-5D), Bipolar Knowledge and Attitudes and Questionnaire (BKAQ), and a self-reported measure of medication adherence (Morisky Medication Adherence Scale-4 items, MMAS-4). Effect sizes were derived from baseline adjusted standardized regression coefficients. Results: Retention in the study was good, 80% of patients in the TAU follow-up assessment and 100% of patients in the CaPE group attended all 12 sessions. Patient satisfaction was higher in the CaPE group relative to control (ES = 1.41). Further, there were large effect sizes shown for CaPE versus TAU for medication adherence (MMAS-4: ES = 0.81), knowledge and attitudes towards bipolar (BKAQ: ES = 0.68), mania (YMRS: ES = 1.18), depression (BDI: ES = 1.17) and quality of life measures (EQ-5D: ES ⇒ 0.88). Conclusions: Culturally adapted psychoeducation intervention is acceptable and feasible, and can be effective in improving mood symptoms and knowledge and attitudes to BPAD when compared with TAU. Larger scale studies are needed to confirm our findings. Trial registration. Clinicaltrials.gov identifier NCT02210390
- 1 December 2015
- Vol. 65 (12) , 1339-1343
Implementation of the Mental Health Act; are we ready?
After the 18th amendment in the constitution health becomes a provincial subject in Pakistan. Sindh Provincial Assembly took the lead and passed the Mental Health Act on 19th September 2013. On 10 April 2015, Sindh assembly passed an amendment that a person who attempts to kill himself or be accused of blasphemy should be examined by a psychiatrist and given treatment if found suffering from a mental illness. It is clear that the act is aimed to help in improving the delivery of mental health care and to protect the rights of mentally ill individuals. Will it meet its intended aims? We have discussed the challenges that lie ahead with special reference to Pakistan. Until we understand these challenges, we will not be able to propose the possible solutions to reach the intended goal of this Act and could avoid the failure of implementation of a similar law "the Mental Health Ordinance 2001".
- 1 December 2015
- Vol. 65 (12) , 1339-1343
Implementation of the Mental Health Act; are we ready?
After the 18th amendment in the constitution health becomes a provincial subject in Pakistan. Sindh Provincial Assembly took the lead and passed the Mental Health Act on 19th September 2013. On 10 April 2015, Sindh assembly passed an amendment that a person who attempts to kill himself or be accused of blasphemy should be examined by a psychiatrist and given treatment if found suffering from a mental illness. It is clear that the act is aimed to help in improving the delivery of mental health care and to protect the rights of mentally ill individuals. Will it meet its intended aims? We have discussed the challenges that lie ahead with special reference to Pakistan. Until we understand these challenges, we will not be able to propose the possible solutions to reach the intended goal of this Act and could avoid the failure of implementation of a similar law "the Mental Health Ordinance 2001".
- Open Access
- 15 September 2015
- Published by Springer Nature in Trials
- Vol. 16 (1) , 1-5
Minocycline as an adjunct for treatment-resistant depressive symptoms: study protocol for a pilot randomised controlled trial
Depression is one of the leading causes of disability worldwide. A high proportion of patients do not respond to standard drug treatments. Recent evidence has suggested that anti-inflammatory treatment may have beneficial effects in major depression. Minocycline is a tetracycline antibiotic with good CNS penetration that exerts effects on multiple interacting symptoms implicated in the pathophysiology of mood disorders. Open-label studies have suggested that minocycline is effective as an adjunct drug in improving depressive symptoms. This is a multi-centre, 3-month, double-blind, placebo-controlled, pilot trial of minocycline added to treatment as usual for patients suffering from DSM-IV major depressive disorder. This will be a double-blind, randomised, controlled, two parallel-arm study with 20 participants in each arm, giving a total of 40 participants. There will be a screening visit, a randomization visit and four follow-up visits. Clinical assessments using the Hamilton Depression Rating Scale (HAM-D), Clinical Global Impression scale (CGI), Patient Health Questionnaire-9 (PHQ −9) and the Generalised Anxiety Disorder scale (GAD-7) will be carried out at every visit. Side effects checklists will also be undertaken at each visit. Biomarkers (inflammatory cytokines and CRP) will be measured at baseline and at the end of the treatment phase. Minocycline will be started at 100 mg once daily (OD) and will be increased to 200 mg at two weeks. Anti-inflammatory treatments have been shown to have some beneficial effects in the treatment of major depressive disorder. The aim of this pilot randomised controlled trial is to establish the degree of improvement in depressive symptoms with the addition of minocycline to treatment as usual. ClinicalTrials.gov NCT02263872 registered 10 October 2014.
- 15 September 2015
- Published by Springer Nature in Trials
- Vol. 16 (1) , 1-5
Open AccessMinocycline as an adjunct for treatment-resistant depressive symptoms: study protocol for a pilot randomised controlled trial
Depression is one of the leading causes of disability worldwide. A high proportion of patients do not respond to standard drug treatments. Recent evidence has suggested that anti-inflammatory treatment may have beneficial effects in major depression. Minocycline is a tetracycline antibiotic with good CNS penetration that exerts effects on multiple interacting symptoms implicated in the pathophysiology of mood disorders. Open-label studies have suggested that minocycline is effective as an adjunct drug in improving depressive symptoms. This is a multi-centre, 3-month, double-blind, placebo-controlled, pilot trial of minocycline added to treatment as usual for patients suffering from DSM-IV major depressive disorder. This will be a double-blind, randomised, controlled, two parallel-arm study with 20 participants in each arm, giving a total of 40 participants. There will be a screening visit, a randomization visit and four follow-up visits. Clinical assessments using the Hamilton Depression Rating Scale (HAM-D), Clinical Global Impression scale (CGI), Patient Health Questionnaire-9 (PHQ −9) and the Generalised Anxiety Disorder scale (GAD-7) will be carried out at every visit. Side effects checklists will also be undertaken at each visit. Biomarkers (inflammatory cytokines and CRP) will be measured at baseline and at the end of the treatment phase. Minocycline will be started at 100 mg once daily (OD) and will be increased to 200 mg at two weeks. Anti-inflammatory treatments have been shown to have some beneficial effects in the treatment of major depressive disorder. The aim of this pilot randomised controlled trial is to establish the degree of improvement in depressive symptoms with the addition of minocycline to treatment as usual. ClinicalTrials.gov NCT02263872 registered 10 October 2014.
- Open Access
- 7 January 2015
- Published by Springer Nature in Trials
- Vol. 16 (1) , 9
A randomised double-blind placebo-controlled 12- week feasibility trial of methotrexate added to treatment as usual in early schizophrenia: study protocol for a randomised controlled trial
Methotrexate is a commonly used anti-inflammatory and immunosuppressive drug. There is growing evidence that inflammatory processes are involved in the pathogenesis of schizophrenia. In our recent randomised double-blind placebo-controlled clinical trial in Pakistan and Brazil, the addition of minocycline (antibiotic and anti-inflammatory drug) for 1 year to treatment as usual reduced negative symptoms and improved some cognitive measures. A meta-analysis of cytokine changes in the peripheral blood has identified IL-2, IFN-gamma, TNF-alpha and soluble IL-2 receptor as trait markers of schizophrenia because their levels were elevated during acute exacerbations and reduced in remission. This suggests immune activation and an inflammatory syndrome in schizophrenia. Based on the evidence of the strong anti-inflammatory properties of methotrexate, we propose that low-dose methotrexate may be an effective therapy in early schizophrenia. This is a double-blind placebo-controlled study of methotrexate added to treatment as usual for patients suffering from schizophrenia, schizoaffective disorder, psychosis not otherwise specified or schizophreniform disorder. This will be with 72 patients, 36 in each arm over 3 months. There will be screening, randomisation and follow-up visits. Full clinical assessments will be carried out at baseline, 2, 4, 8 and 12 weeks. Social and cognitive assessments will be carried out at baseline and 12 weeks. Methotrexate will be given at a dose of 10 mgs orally once a week for a 3-month period. Evidence suggests inflammatory processes are involved in the pathogenesis of schizophrenia and anti-inflammatory treatments have shown to have some beneficial effects. Methotrexate is a known immunosuppressant and anti-inflammatory drug. The aim of this study is to establish the degree of improvement in positive and negative symptoms, as well as cognitive functioning with the addition of methotrexate to treatment as usual. ClinicalTrials.gov identifier: NCT02074319 (24 February 2014).
- 7 January 2015
- Published by Springer Nature in Trials
- Vol. 16 (1) , 9
Open AccessA randomised double-blind placebo-controlled 12- week feasibility trial of methotrexate added to treatment as usual in early schizophrenia: study protocol for a randomised controlled trial
Methotrexate is a commonly used anti-inflammatory and immunosuppressive drug. There is growing evidence that inflammatory processes are involved in the pathogenesis of schizophrenia. In our recent randomised double-blind placebo-controlled clinical trial in Pakistan and Brazil, the addition of minocycline (antibiotic and anti-inflammatory drug) for 1 year to treatment as usual reduced negative symptoms and improved some cognitive measures. A meta-analysis of cytokine changes in the peripheral blood has identified IL-2, IFN-gamma, TNF-alpha and soluble IL-2 receptor as trait markers of schizophrenia because their levels were elevated during acute exacerbations and reduced in remission. This suggests immune activation and an inflammatory syndrome in schizophrenia. Based on the evidence of the strong anti-inflammatory properties of methotrexate, we propose that low-dose methotrexate may be an effective therapy in early schizophrenia. This is a double-blind placebo-controlled study of methotrexate added to treatment as usual for patients suffering from schizophrenia, schizoaffective disorder, psychosis not otherwise specified or schizophreniform disorder. This will be with 72 patients, 36 in each arm over 3 months. There will be screening, randomisation and follow-up visits. Full clinical assessments will be carried out at baseline, 2, 4, 8 and 12 weeks. Social and cognitive assessments will be carried out at baseline and 12 weeks. Methotrexate will be given at a dose of 10 mgs orally once a week for a 3-month period. Evidence suggests inflammatory processes are involved in the pathogenesis of schizophrenia and anti-inflammatory treatments have shown to have some beneficial effects. Methotrexate is a known immunosuppressant and anti-inflammatory drug. The aim of this study is to establish the degree of improvement in positive and negative symptoms, as well as cognitive functioning with the addition of methotrexate to treatment as usual. ClinicalTrials.gov identifier: NCT02074319 (24 February 2014).
- 19 July 2013
- Published by Cambridge University Press (CUP) in Behavioural and Cognitive Psychotherapy
- Vol. 42 (6) , 693-705
Antidepressant and Group Psychosocial Treatment for Depression: A Rater Blind Exploratory RCT from a Low Income Country
Background:Research in the West shows that group psychological intervention together with an antidepressant treatment leads to more effective treatment of a depressive disorder. There are no treatment trials from low income countries comparing the efficacy of antidepressant treatment with a group psychological intervention.Aim:To conduct a feasibility trial to compare the efficacy of an antidepressant to a group psychosocial intervention, for low income women attending primary health care in Karachi, Pakistan.Method:This was a preliminary RCT in an urban primary health care clinic in Karachi, Pakistan. Consecutive eligible women scoring >12 on the CIS-R and >18 on Hamilton Depression Rating Scale (HDRS) (n= 66) were randomly assigned to antidepressants or a psychosocial treatment in group settings. The primary outcome measure was HDRS score; secondary outcome measures were disability and quality of life.Results:More than half of the patients in both groups improved (50% reduction in HDRS scores); at end of therapy at 3 months 19 (59.4%) vs 18 (56.2%), and at 6-month follow-up 21(67.7%) vs 20(62.5%) for antidepressants and psychosocial intervention respectively. Although HDRS, BDQ and EQ5-D scores all improved considerably in both groups from start to end of treatment, and these improvements were largely maintained after a further 3 months, the differences between the two treatments were not statistically significant.Conclusion:Psychosocial intervention was as effective as antidepressants in reducing depression and in improving quality of life and disability at the end of therapy. However, these findings need further exploration through a larger trial.
- 19 July 2013
- Published by Cambridge University Press (CUP) in Behavioural and Cognitive Psychotherapy
- Vol. 42 (6) , 693-705
Antidepressant and Group Psychosocial Treatment for Depression: A Rater Blind Exploratory RCT from a Low Income Country
Background:Research in the West shows that group psychological intervention together with an antidepressant treatment leads to more effective treatment of a depressive disorder. There are no treatment trials from low income countries comparing the efficacy of antidepressant treatment with a group psychological intervention.Aim:To conduct a feasibility trial to compare the efficacy of an antidepressant to a group psychosocial intervention, for low income women attending primary health care in Karachi, Pakistan.Method:This was a preliminary RCT in an urban primary health care clinic in Karachi, Pakistan. Consecutive eligible women scoring >12 on the CIS-R and >18 on Hamilton Depression Rating Scale (HDRS) (n= 66) were randomly assigned to antidepressants or a psychosocial treatment in group settings. The primary outcome measure was HDRS score; secondary outcome measures were disability and quality of life.Results:More than half of the patients in both groups improved (50% reduction in HDRS scores); at end of therapy at 3 months 19 (59.4%) vs 18 (56.2%), and at 6-month follow-up 21(67.7%) vs 20(62.5%) for antidepressants and psychosocial intervention respectively. Although HDRS, BDQ and EQ5-D scores all improved considerably in both groups from start to end of treatment, and these improvements were largely maintained after a further 3 months, the differences between the two treatments were not statistically significant.Conclusion:Psychosocial intervention was as effective as antidepressants in reducing depression and in improving quality of life and disability at the end of therapy. However, these findings need further exploration through a larger trial.
- Open Access
- 1 January 2013
- Published by Springer Nature in Trials
- Vol. 14 (1) , 101
Ondansetron and simvastatin added to treatment as usual in patients with schizophrenia: study protocol for a randomized controlled trial
Negative symptoms and cognitive deficits are two partially-related features of schizophrenia which have a major negative impact on social function and objective quality of life. Standard drug treatments have little impact on either. There is some evidence that anti-inflammatory treatment may have beneficial effects in schizophrenia and major depression. Statins are cholesterol-lowering agents that have been found to be anti-inflammatory agents and are also known to decrease C-reactive protein (CRP). Ondansetron is a serotonin (5-HT3) receptor antagonist widely used to prevent nausea and vomiting in patients receiving chemotherapy for cancer. Small studies have suggested that ondansetron is effective as an adjunct drug in improving the symptoms of schizophrenia.
- 1 January 2013
- Published by Springer Nature in Trials
- Vol. 14 (1) , 101
Open AccessOndansetron and simvastatin added to treatment as usual in patients with schizophrenia: study protocol for a randomized controlled trial
Negative symptoms and cognitive deficits are two partially-related features of schizophrenia which have a major negative impact on social function and objective quality of life. Standard drug treatments have little impact on either. There is some evidence that anti-inflammatory treatment may have beneficial effects in schizophrenia and major depression. Statins are cholesterol-lowering agents that have been found to be anti-inflammatory agents and are also known to decrease C-reactive protein (CRP). Ondansetron is a serotonin (5-HT3) receptor antagonist widely used to prevent nausea and vomiting in patients receiving chemotherapy for cancer. Small studies have suggested that ondansetron is effective as an adjunct drug in improving the symptoms of schizophrenia.